Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company’s United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).


TSXV:MPH - Post by User

Bullboard Posts
Comment by eSnowdenon Jan 20, 2020 8:42am
146 Views
Post# 30572540

RE:Enterprise Value to Sales for Pharmaceuticals ( Drugs )

RE:Enterprise Value to Sales for Pharmaceuticals ( Drugs )
I am a bit more critical of the company for one reason only...look at the 3 year price chart of medicure. The only person who might like this chart is a downhill skier. Now, I am grateful for the tender offer, which I took full advantage of....so in a sense, the CEO is cognizant of the abysmal share price. I just wish the co. had more going for it. The primary cash cow, aggrastat, has it's patent expiring in 2023. ReDs sales trajectory is poor, a decline from $100k to substantially below that means that willingness to adopt this tech. is not there--meaning there is already a viable alternative. And honestly, who needs another statin with so many cheap alternatives already on the market. I'm negative on the company for a reason.
Bullboard Posts